Infusystems Holdings, Inc. · AMEX:INFU
Infusystems — InfuSystem Holdings — Investor Presentation (September 2020)
23 slides from Infusystems's investor presentation, Sep 1, 2020
Slide 1: Investor Presentation
‘uSystem SMART. TRUSTED. Enabling Continuity of Care for Patients, From the Clinic to Their Home Investor Presentation September 2020 | (NYSE American:INFU)
Slide 2: Forward-Looking Statement / Non-GAAP Measures
Forward-Looking Statement / Non-GAAP Measures Forward-Looking Statement Cerin statements contained inthis presentation are forward-looking statements within the meaning of Section 274 of the Secures Act of 1933, as amended and Section 21E ofthe Secure Exchange Act of 1938, sr amended, suchas sateats
Slide 3: Investment Highlights
Market Cap" > $285M Investment Highlights BZ] Enabling continuity of patient care from the hosptal/linc into the home by providing durable medical equipment (DME), including ambulatory infusion pumps and related services Fh] Growing $108 North American home infusion therapy market driven by rising h
Slide 4: InfuSystem: Who We Are
InfuSystem: Who We Are Leading North American provider of services and solutions facilitating outpatient care Double-digit growth through two proven business platforms: Durable Medical Equipment (DME) & Integrated Therapy Services (ITS) Third-party payer contracts covering nearly 95% of the U.S. pop
Slide 5: Two Proven Business Platforms
Two Proven Business Platforms Growth Driven by Market Share Gains and New Therapy Opportunities DME $29.6M (36%) DURABLE MEDICAL EQUIPMENT (DME) SUPPORT SERVICES ITS $51.5M (64%) Total 2019 Equipment and consumable Revenue: sales/lease to hospitals, clinics INTEGRATED THERAPY SERVICES (ITS) $81.1 Mi
Slide 6: DME Platform
DME Platform Traditional Medical Distribution, Lower-Margin, High-Turn Model Source Devices ply Consumables to Device Repair & 4 | p Maintenance 2 Hospitals & Clinics © Pump rentals and VAR sales (new devices) © Broker/trader sales (used devices) @ Biomedical service and repair © Direct payer model,
Slide 7: ITS Platform
ITS Platform Unique and Scalable, High-Margin, High-Service Model e Management Device Repair & = = Maintenance i @ supply medical equipment and proprietary consumables for outpatient care @ Hospital, clinician and patient customer service © Third-party payer model, INFU is paid by the patient's medi
Slide 8: Competitive Advantages
Competitive Advantages Significant Barriersto Entry Based on Unique Focus, National Scale and Established Payer Network 150 9001 Certtied and CHAP Cored. “The patient is at the center of everything we do.” CinfuSystem
Slide 9: Continuing to Leverage the ITS Platform
Continuing to Leverage the ITS Platform Growth Strategy to Address Additional Therapy Segments Goto rket Strategy launch | Growth tracton | fstabibed ‘Oncology Pain Management Negative Pressure ‘Wound Therapy Future Therapies > $81.1 million 2019 revenue ae e8: oe eg ent bee le |__— over $900mition
Slide 10: Synergistic Infrastructure
Synergistic Infrastructure Leveraging Existing Infrastructure to Layer in New Therapies With Minimal Added Expense Clinical Team Revenue Cycle Team Biomedical Team Logistics Team Sales Team Oncology Pain Management Negative Pressure Wound Future Therapies —
Slide 11: ITS Model: Platform Proven in Oncology
ITS Model: Platform Proven in Oncology InfuSystem ITS Value Proposition Opportunity: Oncology Home Treatment + Large capital expense for clinics in addition to maintenance and nightly triage + Reduced staff available to help patients with infusion pump questions and billing Solution: Outpatient Trea
Slide 12: Well-Diversified & Strategic Payer Relationships
Well-Diversified & Strategic Payer Relationships % Cash Collected by Payer 2019 Medicaid: 1.1% y | Private Pay: 2.4% ~ 6,500 Direct Pay Hospital and Alternate Site Customers Hospital / Alternate a a Commercial Payer: 47.7% No Single Payer Greater than 10.9% CinfuSystem
Slide 13: Second Quarter Financial Results
Second Quarter Financial Results Net Revenue Net Income AEBITDA” Op Cash Flow (2) See Aopendic A. 2020 2019 2020 2019 2020 2019 2020 2019 526.0M a $1971 ME 4.1m 1$0.3m ME sss ME sas
Slide 14: First Half Financial Results
First Half Financial Results MM S47. Net Revenue ca me 2019 ES <37.01 | 3.7M. Net Income (loss) amen s 2019 Ii ($0.6m) C 2020 s12.5u AEBITDS 2019 A 57.50 2020 MEE s4.3m Op Cash Flow 2019 MM $4.3m (0) se Aopen
Slide 15: Full Year Financial Results
Full Year Financial Results Rs sei. Net Revenue ao wm 2018 A $67.1 2019 Hf $1.4m N let Income (loss) 2018 Wl ($1) ° 2019 ME sis.2m EBITDA 2018 MEM si3.sm 2019 ME si3.0m Op Cash Flow 2018 MMMM s11.4m (2) See Aopendic A.
Slide 16: Financial Trend & Current 2020 Guidance
Financial Trend & Current 2020 Guidance Net Revenues!!! & AEBITDA\) stone 0 sst0-s9r0 sion os seu 2 000 2 i ses7 sess sora i 2 soo os E g z i - so § soo ss . ra 2018s 20178 20184 20194 2o206 ants a ht ME rte nme 1120162017 conslidatedrevenseshavebeenajstedtoreflectnectfactof headeption of ASC606in 2
Slide 17: Financial Trend & Current Targets
Financial Trend & Current Targets vous) ste, sso $35 s20 st0s vo ss so Hs eo ss soo Cash Flows From Operations 3160-5180 anusnow 9M 0% CinfuSystem
Slide 18: Recent Accomplishments & Corporate Priorities
Recent Accomplishments & Corporate Priorities Dominant market share and sales increases in oncology home therapy market — Late 2018/2019 Proactive patient engagement initiative launched to improve revenue cycle management — 1 2020 Entered negative pressure wound therapy market with partner, Cardinal
Slide 19: Summary
Summary from the clinicinto the home, driving double-digit revenue, cash flow growth and accelerating profit. > ‘Two proven platforms that enable the delivery of patient care Market opportunities driven by rising health care costs, an aging population, medical innovation, patient satisfaction and ot
Slide 20: Executive Team
Executive leam Seasoned Industry Experience Including: Pharmaceutical, Health Care, Life Sciences, Medical Device, Automotive OEM, Public Accounting, Military, Retail, Consumer Brands, Digital Advertising, Consulting & High-Tech (infuSystem
Slide 21: Questions & Answers
SAFE. SMART. TRUSTED? Questions & Answers
Slide 22: Appendix A
Appendix A— Ccerain other nonrecurring corte 308 160 476 1 37 Py 179 GAAP to NON-GAAP Reconciliation [NETINCOME (LOSS) 10 ADIUSTED EBITDA: Twolve Months Ended SikMonths Ended Three Months Ended December 31 June 30 June 30 Ain thousands) 2016 2017 ros 2019 m9 mm 2000 GAAP netincome (loss) (222) (2070
Slide 23: Appendix B — Select Balance Sheet Data
Appendix B — Select Balance Sheet Data ‘Cash and Cash Equivalents Available Liquidity ") ‘Working Capital, Less Cash ‘Medical Equipment, Net Total Assets Total Debt Total Liabilities Total Stockholders’ Equity Outstanding Shares s December 31, 2019 (te Thousands, Except Share Data) 4318 $2,647 13,47
InfuSystem Holdings — Investor Presentation (September 2020) on 6ix